Swift Biosciences SARS-CoV-2 Research Panel
Swift Biosciences has released a research-use targeted sequencing panel for SARS-CoV-2. The amplicon-based multiplex panel targets the full 30 kb viral genome in a single tube, two-hour workflow with two rounds of PCR. More than three hundred primer pairs help increase sensitivity and specificity due to the higher probability of amplifying limited quantities of viral template material, as does the ability to use sequencing to confirm that reads are mappable to SARS-CoV-2 instead of similar coronaviruses or pathogens, the company said. Swift's workflow also adds sequencing adapters directly without the need for a secondary library construction.